{"id":"naloxone-hcl-pr-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Withdrawal symptoms (agitation, body aches, anxiety)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naloxone competitively binds to mu, delta, and kappa opioid receptors with highest affinity for mu receptors, displacing opioids and preventing their pharmacological effects. The PR (prolonged-release) formulation extends the duration of action, allowing for less frequent dosing compared to immediate-release naloxone. This is particularly useful for chronic opioid overdose prevention and opioid use disorder management.","oneSentence":"Naloxone HCl is a competitive opioid receptor antagonist that blocks the effects of opioids by binding to opioid receptors without activating them.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:37.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid overdose reversal"},{"name":"Opioid use disorder maintenance treatment"},{"name":"Prevention of opioid overdose in at-risk populations"}]},"trialDetails":[{"nctId":"NCT01885182","phase":"PHASE3","title":"Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2013-06-01","conditions":"Cancer, Pain","enrollment":232},{"nctId":"NCT02880475","phase":"PHASE1","title":"OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2014-06-01","conditions":"Chronic Pain","enrollment":30},{"nctId":"NCT01197261","phase":"PHASE2","title":"OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2010-09","conditions":"Interstitial Cystitis, Painful Bladder Syndrome, Pain","enrollment":120},{"nctId":"NCT01438567","phase":"PHASE3","title":"A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2011-09","conditions":"Pain, Constipation","enrollment":270},{"nctId":"NCT01112644","phase":"PHASE3","title":"Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2010-04","conditions":"Moderate to Severe Idiopathic RLS With Daytime Symptoms","enrollment":205},{"nctId":"NCT00902837","phase":"PHASE3","title":"OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2009-05","conditions":"Chronic Osteoarthritis","enrollment":181},{"nctId":"NCT03687268","phase":"PHASE3","title":"Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation","status":"UNKNOWN","sponsor":"Develco Pharma Schweiz AG","startDate":"2017-07-31","conditions":"Opioid-Induced Constipation","enrollment":1500},{"nctId":"NCT02321397","phase":"PHASE2, PHASE3","title":"To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2014-11","conditions":"Malignant Pain, Non-malignant Pain","enrollment":155},{"nctId":"NCT01915147","phase":"PHASE2","title":"A Study to Explore the Influence of Two Opioid Pain Medications on Bacterial Composition in the Gut and Other Gastrointestinal Aspects","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2013-07","conditions":"Severe Chronic Pain","enrollment":108},{"nctId":"NCT01014559","phase":"PHASE3","title":"Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients","status":"TERMINATED","sponsor":"Mundipharma SAS","startDate":"2010-02","conditions":"Constipation, Pain","enrollment":225},{"nctId":"NCT01439100","phase":"PHASE3","title":"A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2011-10","conditions":"Parkinson's Disease With Severe Pain","enrollment":172},{"nctId":"NCT01083485","phase":"PHASE4","title":"OXN PR Compared to OXY PR in Subjects With Postoperative Pain After Knee Arthroplasty","status":"COMPLETED","sponsor":"Mundipharma Oy","startDate":"2010-03","conditions":"Post Operative Pain","enrollment":137},{"nctId":"NCT00784810","phase":"PHASE4","title":"A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis","status":"COMPLETED","sponsor":"Napp Pharmaceuticals Limited","startDate":"2009-02","conditions":"Osteoarthritis, Back Pain","enrollment":247}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Naloxone HCl PR tablets","genericName":"Naloxone HCl PR tablets","companyName":"Develco Pharma Schweiz AG","companyId":"develco-pharma-schweiz-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naloxone HCl is a competitive opioid receptor antagonist that blocks the effects of opioids by binding to opioid receptors without activating them. Used for Opioid overdose reversal, Opioid use disorder maintenance treatment, Prevention of opioid overdose in at-risk populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}